Trade Spero Therapeutics, Inc. - SPRO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 0.68-9.00 |
| Average Volume (10 days) | 591.67K |
| Average Volume (3 months) | 9.03M |
| Market Cap | 70.93M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 51.78M |
| Revenue | 8.81M |
| EPS | -3.11 |
| Dividend (Yield %) | N/A |
| Beta | 0.89 |
| Next Earnings Date | Mar 30, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Spero Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total revenue | 18.256 | 9.33 | 18.147 | 3.966 | 1.979 |
| Revenue | 18.256 | 9.33 | 18.147 | 3.966 | 1.979 |
| Total Operating Expense | 106.227 | 88.443 | 81.363 | 46.772 | 43.709 |
| Selling/General/Admin. Expenses, Total | 41.701 | 21.44 | 15.588 | 12.887 | 10.84 |
| Research & Development | 64.526 | 67.003 | 65.775 | 33.885 | 32.869 |
| Operating Income | -87.971 | -79.113 | -63.216 | -42.806 | -41.73 |
| Interest Income (Expense), Net Non-Operating | -1.39 | 0.401 | 1.551 | 0 | 1.541 |
| Other, Net | -0.395 | 0.432 | 0.74 | 1.144 | 0.303 |
| Net Income Before Taxes | -89.756 | -78.28 | -60.925 | -41.662 | -39.886 |
| Net Income After Taxes | -89.756 | -78.28 | -60.925 | -41.662 | -39.886 |
| Minority Interest | 0 | 1.143 | |||
| Net Income Before Extra. Items | -89.756 | -78.28 | -60.925 | -41.662 | -38.743 |
| Net Income | -89.756 | -78.28 | -60.925 | -41.662 | -38.743 |
| Total Adjustments to Net Income | 0 | -0.549 | 0 | -7.354 | |
| Income Available to Common Excl. Extra. Items | -89.756 | -78.829 | -60.925 | -41.662 | -46.097 |
| Income Available to Common Incl. Extra. Items | -89.756 | -78.829 | -60.925 | -41.662 | -46.097 |
| Dilution Adjustment | |||||
| Diluted Net Income | -89.756 | -78.829 | -60.925 | -41.662 | -46.097 |
| Diluted Weighted Average Shares | 30.8958 | 22.3861 | 18.1605 | 16.0018 | 14.3692 |
| Diluted EPS Excluding Extraordinary Items | -2.90512 | -3.52133 | -3.3548 | -2.60358 | -3.20805 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -2.90512 | -3.52133 | -3.3548 | -2.60358 | -3.20805 |
| Total Extraordinary Items | 0 | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 2.069 | 2.744 | 3.064 | 5.148 | 7.3 |
| Revenue | 2.069 | 2.744 | 3.064 | 5.148 | 7.3 |
| Total Operating Expense | 32.276 | 30.246 | 25.588 | 23.69 | 26.703 |
| Selling/General/Admin. Expenses, Total | 15.305 | 13.021 | 11.152 | 9.229 | 8.299 |
| Research & Development | 16.971 | 17.225 | 14.436 | 14.461 | 18.404 |
| Operating Income | -30.207 | -27.502 | -22.524 | -18.542 | -19.403 |
| Interest Income (Expense), Net Non-Operating | -2.609 | -1.66 | 0.09 | 0.082 | 0.098 |
| Other, Net | -0.013 | -0.078 | -0.087 | -0.112 | -0.118 |
| Net Income Before Taxes | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
| Net Income After Taxes | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
| Net Income Before Extra. Items | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
| Net Income | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
| Income Available to Common Excl. Extra. Items | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
| Income Available to Common Incl. Extra. Items | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
| Diluted Net Income | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
| Diluted Weighted Average Shares | 32.6067 | 32.3311 | 32.1325 | 29.6754 | 29.4142 |
| Diluted EPS Excluding Extraordinary Items | -1.00682 | -0.90439 | -0.70088 | -0.62584 | -0.66033 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.00682 | -0.90439 | -0.70088 | -0.62584 | -0.66033 |
| Total Adjustments to Net Income | 0 | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 157.872 | 139.145 | 95.414 | 124.219 | 92.059 |
| Cash and Short Term Investments | 146.402 | 126.906 | 82.045 | 115.443 | 87.288 |
| Cash & Equivalents | 112.584 | 85.209 | 29.73 | 34.08 | 87.288 |
| Total Receivables, Net | 2.641 | 6.176 | 8.546 | 1.298 | 2.943 |
| Prepaid Expenses | 8.829 | 6.063 | 4.823 | 7.478 | 1.828 |
| Total Assets | 171.072 | 153.451 | 106.103 | 129.006 | 93.479 |
| Property/Plant/Equipment, Total - Net | 7.556 | 8.783 | 7.148 | 2.893 | 1.164 |
| Property/Plant/Equipment, Total - Gross | 10.436 | 11.059 | 8.663 | 3.72 | 1.807 |
| Accumulated Depreciation, Total | -2.88 | -2.276 | -1.515 | -0.827 | -0.643 |
| Note Receivable - Long Term | 0 | 0.311 | 0.021 | 0.233 | 0 |
| Other Long Term Assets, Total | 5.644 | 5.212 | 3.52 | 1.661 | 0.256 |
| Total Current Liabilities | 18.67 | 14.343 | 26.663 | 12.318 | 8.157 |
| Accounts Payable | 1.101 | 1.155 | 4.147 | 3.603 | 3.47 |
| Accrued Expenses | 15.712 | 13.188 | 22.516 | 8.263 | 4.321 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.857 | 0 | 0.452 | 0.366 | |
| Total Liabilities | 82.783 | 21.411 | 31.529 | 13.506 | 8.877 |
| Total Long Term Debt | 48.414 | 0 | 0 | 0 | 0 |
| Minority Interest | 0.355 | 0.355 | |||
| Other Liabilities, Total | 15.699 | 7.068 | 4.866 | 0.833 | 0.365 |
| Total Equity | 88.289 | 132.04 | 74.574 | 115.5 | 84.602 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Common Stock | 0.032 | 0.029 | 0.019 | 0.017 | 0.014 |
| Additional Paid-In Capital | 455.719 | 409.722 | 273.966 | 254.013 | 181.428 |
| Retained Earnings (Accumulated Deficit) | -367.463 | -277.707 | -199.427 | -138.502 | -96.84 |
| Total Liabilities & Shareholders’ Equity | 171.072 | 153.451 | 106.103 | 129.006 | 93.479 |
| Total Common Shares Outstanding | 32.3937 | 29.2603 | 19.1907 | 17.206 | 14.3692 |
| Short Term Investments | 33.818 | 41.697 | 52.315 | 81.363 | |
| Other Equity, Total | -0.002 | -0.007 | 0.016 | -0.028 | |
| Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | |||
| Total Preferred Shares Outstanding | 3.21815 | 3.21829 | |||
| Long Term Debt | 48.414 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 132.704 | 157.872 | 131.769 | 106.316 | 129.492 |
| Cash and Short Term Investments | 121.966 | 146.402 | 123.417 | 99.218 | 115.676 |
| Cash & Equivalents | 72.111 | 112.584 | 112.859 | 71.562 | 77.042 |
| Short Term Investments | 49.855 | 33.818 | 10.558 | 27.656 | 38.634 |
| Total Receivables, Net | 1.991 | 2.641 | 2.584 | 2.197 | 8.622 |
| Prepaid Expenses | 8.747 | 8.829 | 5.768 | 4.901 | 5.194 |
| Total Assets | 145.83 | 171.072 | 144.691 | 119.594 | 143.44 |
| Property/Plant/Equipment, Total - Net | 7.197 | 7.556 | 7.71 | 8.067 | 8.425 |
| Note Receivable - Long Term | 0 | 0 | 0 | 0.311 | |
| Other Long Term Assets, Total | 5.929 | 5.644 | 5.212 | 5.211 | 5.212 |
| Total Current Liabilities | 69.199 | 18.67 | 17.258 | 12.826 | 17.763 |
| Accounts Payable | 4.78 | 1.101 | 3.161 | 1.632 | 3.825 |
| Accrued Expenses | 10.429 | 15.712 | 12.398 | 10.015 | 13.938 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 83.357 | 82.783 | 32.796 | 29.342 | 24.594 |
| Total Long Term Debt | 0 | 48.414 | 0 | 0 | 0 |
| Other Liabilities, Total | 14.158 | 15.699 | 15.538 | 16.516 | 6.831 |
| Total Equity | 62.473 | 88.289 | 111.895 | 90.252 | 118.846 |
| Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
| Common Stock | 0.033 | 0.032 | 0.032 | 0.03 | 0.03 |
| Additional Paid-In Capital | 462.735 | 455.719 | 450.085 | 405.923 | 415.946 |
| Retained Earnings (Accumulated Deficit) | -400.292 | -367.463 | -338.223 | -315.702 | -297.13 |
| Other Equity, Total | -0.006 | -0.002 | -0.002 | -0.002 | -0.003 |
| Total Liabilities & Shareholders’ Equity | 145.83 | 171.072 | 144.691 | 119.594 | 143.44 |
| Total Common Shares Outstanding | 32.7556 | 32.3937 | 32.2203 | 29.6992 | 29.6639 |
| Total Preferred Shares Outstanding | 3.21815 | 3.21815 | 3.21815 | 3.21815 | 3.21815 |
| Other Current Liabilities, Total | 53.99 | 1.857 | 1.699 | 1.179 | |
| Long Term Debt | 0 | 48.414 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -89.756 | -78.28 | -60.925 | -41.662 | -39.886 |
| Cash From Operating Activities | -64.347 | -85.872 | -50.02 | -39.625 | -39.111 |
| Cash From Operating Activities | 0.646 | 0.761 | 0.75 | 0.409 | 0.363 |
| Non-Cash Items | 11.901 | 5.111 | 3.376 | 2.699 | -0.031 |
| Changes in Working Capital | 12.862 | -13.464 | 6.779 | -1.071 | 0.443 |
| Cash From Investing Activities | 7.672 | 10.47 | 29.53 | -83.156 | -0.027 |
| Capital Expenditures | -0.157 | -0.314 | -2.436 | -0.027 | |
| Cash From Financing Activities | 84.05 | 130.881 | 16.14 | 69.523 | 116.111 |
| Financing Cash Flow Items | 47.232 | -0.953 | -0.158 | -1.312 | -4.749 |
| Issuance (Retirement) of Stock, Net | 36.818 | 131.834 | 16.298 | 70.835 | 120.86 |
| Net Change in Cash | 27.375 | 55.479 | -4.35 | -53.258 | 76.973 |
| Other Investing Cash Flow Items, Total | 7.672 | 10.627 | 29.844 | -80.72 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -32.829 | -89.756 | -60.516 | -37.995 | -19.423 |
| Cash From Operating Activities | -28.223 | -64.347 | -36.998 | -32.046 | -15.479 |
| Cash From Operating Activities | 0.189 | 0.646 | 0.455 | 0.307 | 0.159 |
| Non-Cash Items | 6.117 | 11.901 | 7.327 | 4.708 | 2.253 |
| Changes in Working Capital | -1.7 | 12.862 | 15.736 | 0.934 | 1.532 |
| Cash From Investing Activities | -16.064 | 7.672 | 30.947 | 13.922 | 3.003 |
| Other Investing Cash Flow Items, Total | -16.064 | 7.672 | 30.947 | 13.922 | 3.003 |
| Cash From Financing Activities | 3.814 | 84.05 | 33.701 | 4.477 | 4.309 |
| Financing Cash Flow Items | 0 | 47.232 | -0.411 | -0.146 | -0.037 |
| Issuance (Retirement) of Stock, Net | 3.814 | 36.818 | 34.112 | 4.623 | 4.346 |
| Net Change in Cash | -40.473 | 27.375 | 27.65 | -13.647 | -8.167 |
| Capital Expenditures | 0 | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| GSK plc | Corporation | 17.7507 | 9190606 | 7450000 | 2022-11-14 | MED |
| Anson Funds Management LP. | Hedge Fund | 5.8321 | 3019608 | 1545736 | 2022-12-31 | HIGH |
| Atlas Venture | Venture Capital | 4.651 | 2408128 | 0 | 2022-12-31 | LOW |
| Pfizer Inc | Corporation | 4.5626 | 2362348 | 0 | 2022-07-20 | MED |
| AWM Investment Company, Inc. | Investment Advisor/Hedge Fund | 2.5116 | 1300400 | -1000000 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0364 | 1054388 | 665 | 2022-12-31 | LOW |
| Alphabet, Inc. | Venture Capital | 1.7189 | 889979 | 0 | 2022-12-31 | LOW |
| Millennium Management LLC | Hedge Fund | 1.6927 | 876398 | 188002 | 2022-12-31 | HIGH |
| Murchinson Ltd. | Investment Advisor/Hedge Fund | 1.4731 | 762700 | 0 | 2022-12-31 | HIGH |
| Rock Springs Capital Management LP | Hedge Fund | 1.2931 | 669533 | -101177 | 2022-12-31 | LOW |
| Mahadevia (Ankit) | Individual Investor | 1.1307 | 585445 | 519628 | 2023-02-03 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.9252 | 479031 | -187473 | 2022-12-31 | LOW |
| Hamed (Kamal) | Individual Investor | 0.9193 | 475957 | 265957 | 2023-02-01 | MED |
| Novo Holdings A/S | Venture Capital | 0.9056 | 468902 | 0 | 2022-12-31 | LOW |
| XTX Markets LLC | Investment Advisor | 0.6697 | 346734 | 346734 | 2022-12-31 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.6623 | 342900 | 128200 | 2022-12-31 | HIGH |
| Keutzer (Timothy) | Individual Investor | 0.6318 | 327144 | 262563 | 2023-02-02 | LOW |
| Joseph (Tamara) | Individual Investor | 0.627 | 324644 | 262563 | 2023-02-02 | LOW |
| Oasis Management Company Ltd. | Investment Advisor/Hedge Fund | 0.5562 | 288000 | 0 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4969 | 257284 | -32974 | 2022-12-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Spero Therapeutics, Inc. Company profile
About Spero Therapeutics Inc
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). It is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The Company also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Spero Therapeutics Inc revenues increased from $7.4M to $15.5M. Net loss applicable to common stockholders decreased less than 1% to $60.5M. Revenues reflect Grant revenue increase of 77% to $12.7M, Collaboration revenue increase from $258K to $2.8M. Net loss reflects Research and development - Balancing val decrease of 44% to $28.8M (expense).
| Industry: | Bio Therapeutic Drugs |
675 Massachusetts Ave Ste 14
CAMBRIDGE
MASSACHUSETTS 02139-3309
US
Income Statement
- Annual
- Quarterly
News
GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com